Angiopohl

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angiopohl

What is Angiopohl?

Angiopohl is a pharmaceutical preparation containing the active substance nitroglycerin, which belongs to a group of medications known as organic nitrates. It is primarily used to manage and alleviate symptoms associated with coronary heart disease.

Mechanism of Action

The active ingredient, nitroglycerin, acts as a vasodilator. It works by relaxing the smooth muscles within the walls of the blood vessels. This relaxation leads to the widening of the veins and, to a lesser extent, the arteries.

By dilating these vessels, the medication facilitates several physiological changes:

  • Reduced Cardiac Workload: By widening the systemic veins, the amount of blood returning to the heart is decreased, which lowers the pressure within the heart chambers.
  • Improved Oxygen Supply: Dilation of the coronary arteries enhances blood flow directly to the heart muscle, improving oxygen delivery to areas that may be receiving an insufficient supply.
  • Lowered Oxygen Demand: Because the heart does not have to pump as hard against reduced systemic resistance, its overall requirement for oxygen decreases.

Therapeutic Use

Angiopohl is used in clinical settings to treat sudden episodes of chest pain, commonly referred to as angina pectoris. These episodes occur when the heart muscle does not receive enough oxygen-rich blood, often due to the narrowing of the coronary arteries.

The medication is designed for rapid onset to provide prompt relief during acute attacks or as a preventive measure shortly before physical exertion or other situations known to trigger angina symptoms. It is available in various formulations, such as sprays or concentrates for solution, depending on the specific clinical requirement and the urgency of the condition.

Regulatory References

  1. Nitroglycerin Sublingual: MedlinePlus Drug Information

What side effects are possible with Angiopohl?

Possible Side Effects and Safety Information

The safety profile of Angiopohl (Nitroglycerin) is defined by its potent vasodilating action, which determines the most frequently documented adverse reactions according to regulatory classifications. Side effects are officially grouped by frequency and affected body system, following standards set by health authorities.


Adverse Reaction Classifications

Frequency Classification Common Adverse Reactions
Very Common (ge 1/10) Headache (often severe)
Common (ge 1/100 to < 1/10) Dizziness, Tachycardia, Hypotension

Adverse reactions involving the Vascular System (e.g., Hypotension, Syncope) and the Nervous System (e.g., Headache) are the most frequently cited in official labeling. Gastrointestinal effects like Nausea and Vomiting are typically classified as uncommon.


Serious Safety Considerations

Regulatory documents highlight rare but serious adverse reactions, including Severe Hypotension, Circulatory Collapse, and a blood disorder known as Methaemoglobinaemia, which is primarily associated with high doses or overdose. A critical safety restriction is the absolute contraindication for use in individuals taking Phosphodiesterase type 5 (PDE5) inhibitors, due to the risk of life-threatening hypotension.

Population and Timing Notes

The label notes that headache is often most prominent at the start of treatment. Additionally, official documents advise caution for older adults due to an increased risk of orthostatic hypotension and for patients with severe Hepatic or Renal Impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding an overdose of Angiopohl (Nitroglycerin) is primarily centered on the risks associated with excessive vasodilation and subsequent circulatory issues.

Documented Overdose Manifestations

Symptoms of overdose, as described in official labeling, include severe hypotension (low blood pressure), a persistent throbbing headache, visual disturbances, flushing, vertigo, and palpitations. Severe exposure can lead to circulatory collapse, resulting in shock, syncope (fainting), and potentially coma or convulsions. A specific, serious complication is Methemoglobinemia, where oxygen transport in the blood is impaired.

Required Emergency Actions

Immediate medical attention must be sought for a suspected overdose.

Regulators emphasize specific circumstances that require prompt medical help during acute use:

  • Seek prompt medical attention if acute chest pain persists after a total of 3 doses (e.g., tablets or sprays) within a 15-minute period.

Management of severe hypotension, a key overdose sign, often involves elevation of the extremities and central volume expansion (e.g., intravenous fluid administration) as supportive measures. Continuous monitoring of blood pressure and heart rate is required. Although there is no known antidote for nitroglycerin overdose itself, Methylene Blue is the defined treatment for documented Methemoglobinemia.

Therapeutic Uses of Angiopohl

What Angiopohl Treats: Main Uses and Benefits

Angiopohl is considered relevant for addressing symptoms related to physical discomfort associated with coronary artery disease. The therapeutic purpose is applied across domains where short-term symptom management is appropriate, assisting patients by easing the overall symptom burden and supporting functional stability.

The medication is commonly used to help with managing acute episodic chest discomfort, addressing exertion-triggered and recurrent symptom patterns, and providing supportive use in heightened cardiovascular states such as unstable angina or acute decompensated heart failure. In the context of angina pectoris, the medication is relevant for easing groups of symptoms that may become intense or disruptive, including squeezing and pressure in the chest that may radiate.

“Angiopohl is applied in scenarios where additional management of discomfort is required, supporting the patient during difficult episodes by easing distress.”

Used proactively, the medication may assist with easing the recurrent nature of symptoms, which contributes to improved comfort during periods of heightened symptoms that might otherwise interfere with daily functioning.


Quick Fact: Relief for Angina Pectoris Symptoms The medication is considered relevant for managing acute episodes of chest pain and pressure that stem from myocardial ischemia, providing symptomatic relief for the physical discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory documents define the eligibility profile of Angiopohl (Nitroglycerin) based on absolute contraindications and status of use in specific populations.

Eligibility Scope

Population Status Regulatory Classification (Examples)
Populations Contraindicated Absolute prohibition for patients using PDE-5 inhibitors (e.g., sildenafil) or sGC stimulators (e.g., riociguat), and those with severe anemia, increased intracranial pressure, or circulatory shock [FDA/EMA].
Age-Related Rules Safety and effectiveness have not been established in pediatric patients (under 18 years). Use in older adults (geriatric) requires caution due to a greater likelihood of reduced organ function [FDA].
Reproductive Status Use in pregnancy is recommended only if clearly needed, and it is not known if the drug is excreted in human milk [FDA].
Conditional Restrictions Use requires caution in patients who are volume-depleted or already hypotensive. Nitrate therapy may aggravate angina caused by Hypertrophic Obstructive Cardiomyopathy [FDA].

Eligibility Classifications (High-Level)

Classification Severity Constraints
Concomitant Drug Use Absolute Prohibition Simultaneous use with PDE-5 or sGC inhibitors
Age-Group Status Use Not Established Pediatric patients

The regulatory profile primarily defines who cannot use Angiopohl by strictly listing absolute contraindications based on critical pre-existing conditions and drug-drug interactions that result in dangerous hypotension. Eligibility is restricted to adult patients who do not have these listed contraindications, with use in other populations requiring careful consideration of the regulatory status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Angiopohl (Nitroglycerin) interacts with several medicinal products and substances, primarily through pharmacodynamic mechanisms that increase the risk of severe hypotension, as defined in regulatory documents.

Contraindicated Combinations

The co-administration of Angiopohl is contraindicated with certain drug classes due to the risk of life-threatening drops in blood pressure (profound vasodilatory potentiation):

Classification Interacting Agents
Prohibited Combinations Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat).

Timing-Based Rule: Regulatory labeling mandates separation from PDE5 inhibitors, with Angiopohl use prohibited within 24 hours of sildenafil or vardenafil, and within 48 hours of tadalafil.

Pharmacodynamic and Exposure-Altering Interactions

Co-administration with other blood pressure-lowering agents, including beta-blockers, calcium channel blockers, and MAOIs, may result in additive hypotensive effects. Consumption of alcohol also carries this risk and is discouraged.

Official documents describe interactions that alter drug exposure or effect:

  • High-dose Aspirin is reported to increase the systemic exposure (AUC and C max) of nitroglycerin, which may enhance its effects.
  • Intravenous Angiopohl may antagonize the anticoagulant effect of intravenous Heparin and reduce the effectiveness of thrombolytic agents (e.g., t-PA).
  • Dihydroergotamine levels may be increased when co-administered with oral nitroglycerin, while Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the therapeutic response to Angiopohl.

Mechanism of Action

The mechanism of Angiopohl begins at the cellular level, where the drug is bioactivated by the ALDH2 enzyme to release the signaling molecule Nitric Oxide (NO). This NO acts directly on vascular smooth muscle cells by binding to and activating the enzyme Soluble Guanylate Cyclase (sGC), thereby triggering the cGMP cascade. This cascade rapidly leads to the dephosphorylation of proteins involved in contraction, resulting in widespread relaxation of the blood vessel walls. The resultant vasodilation is most pronounced in the venous capacitance vessels (veins), causing blood to pool in the peripheral circulation. This venous pooling alters the cardiovascular dynamics by significantly decreasing the volume and pressure of blood returning to the heart, a key physiological change known as reduced preload. The mechanism diminishes the stretch and wall tension of the cardiac muscle, which directly causes a reduction in the heart's oxygen demand.

Dosage and Administration Information

How to Use Angiopohl

Angiopohl (Nitroglycerin) is administered through distinct routes and schedules according to its official formulation, necessitating adherence to precise instructions for proper use. The primary administration methods dictate whether the medicine is used for immediate intervention or as part of a scheduled long-term plan.


Official Administration Guidelines

Feature Official Guidance
Route of administration Sublingual (SL), Oral Spray/Lingual, Intravenous (IV), Transdermal, Oral (Extended-Release).
Dosing schedule Acute/SL: 0.3 mg to 0.6 mg, or 400 mcg, repeated every 5 minutes. Maximum: 3 doses in 15 minutes. IV: Initial 5 mcg/minute, titrated upward. Maintenance/ER: Initial 2.5 mg to 6.5 mg, 3 to 4 times daily.
Special procedural conditions Acute: Administered while the patient is at rest and sitting. SL Forms: Must dissolve under the tongue; must not be chewed, crushed, or swallowed. Oral ER: Must be swallowed whole. IV: Requires a controlled infusion pump.
Age-group administration rules Pediatric Use: Safety and effectiveness are not established. Geriatric Use: Dosing should be cautious, starting at the low end of the range.

Frequency and Long-Term Use Protocol

For chronic maintenance (Oral Extended-Release and Transdermal forms), the use protocol requires a mandatory nitrate-free interval of 10 to 14 hours per day. This cyclic regimen is established to prevent the development of pharmacological tolerance, ensuring the medicine remains effective during the periods it is used. For acute sublingual administration, dosing is based strictly on an as-needed frequency, with a strict limit of three total doses within a quarter-hour period.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Angiopohl

The body of research for Angiopohl (Nitroglycerin) primarily focuses on research concerning acute and episodic changes in the cardiovascular system. The overall evidence landscape consists of a mix of established Randomized Controlled Trials (RCTs) and supportive systematic reviews, with recognized limitations, particularly concerning long-term follow-up.


Evidence for Use in Acute Angina Pectoris and Stable Heart Conditions

Research has long explored the role of Angiopohl in the context of symptoms related to coronary artery disease, specifically for episodes of chest discomfort known as angina pectoris. The structure of the evidence includes initial Randomized Controlled Trials (RCTs) that examined what studies evaluated regarding symptom change and functional measures like exercise capacity in adults. Studies reported measurements of short-term symptom evolution. Research highlights changes measured during the study period, such as observed associations with changes in the time until the onset of angina during controlled exercise testing. A significant research limitation noted is the consistent observation of patterns related to pharmacological tolerance, meaning that the body adjusts to the medicine over time. Data for the medicine's role in preventing long-term major cardiovascular events are not fully established from dedicated, large-scale RCTs.


Evidence for Use in Acute Decompensated Heart Failure Exacerbations

Angiopohl was studied for its supportive role in acute and severe heart conditions, such as Acute Decompensated Heart Failure (AHF) and pulmonary edema. Research in this area is typically structured around Systematic Reviews and Meta-analyses that combine findings from smaller trials. Studies monitored outcomes related to systemic or functional imbalance, specifically focusing on changes in hemodynamic parameters. Findings describe patterns observed in the studies related to the acute symptom management of patients. The evidence for this application is labeled as moderate, which suggests the overall certainty regarding findings remains limited. The outcomes monitored were mainly related to acute symptom management and short-term survival metrics, and findings do not fully establish long-term effects. Research is ongoing to further investigate dosing protocols and their observed outcomes for this patient group.

Key Studies & References

  1. Nitroglycerin Drug Information
  2. Effect of Nitrates in Patients With Heart Failure: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Angiopohl (FAQ)


Q: How quickly should I expect Angiopohl to start working for chest pain?

Angiopohl, in its fast-acting forms like sublingual tablets or spray, is designed for rapid relief. According to official product information, the onset of its effect, which works by widening the blood vessels (vasodilation), typically begins approximately 1 to 3 minutes after the medicine is administered.


Q: How long does the effect of a single dose of Angiopohl typically last?

Official studies on the sublingual forms show that the medicine's effects persist for at least 25 minutes following a single dose. The short duration of effect is consistent with its regulatory designation for acute, as-needed symptom relief.


Q: Is Angiopohl suitable for older adults?

Regulatory documents advise that Angiopohl should be used with caution in older adults. This is due to the potential for reduced organ function and an increased risk of orthostatic hypotension, which is a significant drop in blood pressure upon standing.


Q: Can women who are pregnant or breastfeeding use Angiopohl?

The use of Angiopohl during pregnancy is generally recommended only if it is clearly needed. Official information states it is not known whether the drug is excreted into human milk.


Q: What is Angiopohl used for besides chest pain (angina)?

While Angiopohl is primarily indicated for the relief and prevention of angina pectoris, official regulatory documents indicate that Angiopohl has also been used in the management of high blood pressure during surgical procedures and for acute decompensated heart failure exacerbations.


Q: Are there any long-term side effects associated with Angiopohl use?

Official safety information notes that continued use without an interruption period (nitrate-free interval) may lead to pharmacological tolerance, where the drug's effectiveness may decrease. Additionally, physical dependence has been reported in occupational settings with high exposure, leading to withdrawal symptoms upon cessation.


Q: Does Angiopohl cause dizziness or affect driving ability?

Common side effects of Angiopohl include dizziness and vertigo, which are related to its blood pressure-lowering effects. Because side effects like dizziness may occur, official patient information mentions that activities requiring full alertness should be approached with caution.


Q: Can children or teenagers be prescribed Angiopohl?

According to official regulatory labeling, the safety and effectiveness of Angiopohl have not been established in pediatric patients, defined as those under 18 years of age.


Q: Does alcohol consumption affect the safety or effectiveness of Angiopohl?

Official drug interaction warnings state that consuming alcohol may result in an additive hypotensive effect, which means it can dangerously lower blood pressure. Due to the potential for severe drops in blood pressure, official information cautions against the concurrent use of alcohol with Angiopohl.


Q: What is the risk of tolerance developing with Angiopohl?

Official warnings state that excessive or continuous use may lead to the development of tolerance, making the drug less effective. This is why long-acting forms are prescribed with a mandatory nitrate-free interval each day, to help prevent this issue.


Q: What common household items or chemicals should be kept away from Angiopohl?

Angiopohl sublingual forms should be kept away from excessive heat and fire, as the medication contains volatile solvents. For safety, the containers should not be forcefully opened or burned.


Q: What should I do if I miss a dose of Angiopohl?

If a scheduled dose (such as an extended-release form) is missed, official patient information states that you should typically skip the missed dose and not double up to catch up. Taking more than prescribed can lead to overdosage symptoms.


Q: Is Angiopohl addictive?

Official warnings note that true physical dependence has been reported in individuals with high occupational exposure to nitrates. In these cases, temporary cessation resulted in symptoms of withdrawal, including chest pain.


Q: Can Angiopohl be used for conditions not related to the heart?

While the primary indications relate to heart conditions and hypertension, regulatory information for some forms of nitroglycerin mentions use in conditions not related to the heart, such as a vasodilator for certain localized conditions.


Q: What happens if I accidentally take two doses of Angiopohl close together?

Regulatory documents state that patients should not double a dose. Taking more than prescribed can lead to overdosage symptoms, which include a dangerous and severe drop in blood pressure (profound hypotension).


Q: Is Angiopohl a short-acting or long-acting medication?

Angiopohl is available in multiple forms to serve different needs. It is available in fast-acting forms, such as sublingual tablets and sprays for acute relief, and in long-acting forms like extended-release capsules or transdermal patches for maintenance therapy.


Q: Can Angiopohl be safely used by people with a history of stroke?

Official contraindications state that Angiopohl should not be used in patients with conditions that increase pressure within the skull (intracranial pressure), such as a cerebral hemorrhage. This assessment is made based on the individual's specific medical history.


Q: How do I know if Angiopohl is working effectively for me?

For acute angina, the effectiveness of Angiopohl is primarily measured by the relief of an anginal attack, meaning a reduction or cessation of chest pain. For maintenance therapy, effectiveness relates to the reduction in the frequency and severity of angina episodes.


Q: What happens if Angiopohl is taken past its expiration date?

Regulatory documents advise patients not to keep or use outdated medicine. When Angiopohl, especially the sublingual tablets, is not stored correctly or is past its expiration date, its potency may be significantly reduced.


Q: Does Angiopohl interact with common herbal supplements?

Official patient instructions emphasize the importance of checking with a healthcare provider before starting any new medications or supplements. This is advised because certain supplements may also affect blood pressure or interact with the medicine's mechanism.


Q: How long does it take for Angiopohl to be fully cleared from the system?

Nitroglycerin is cleared from the bloodstream at a very rapid rate. For the sublingual form, the mean serum half-life (the time it takes for half the drug to be eliminated) is extremely short, approximately 2 to 3 minutes.


Q: Why do some people feel flushed or warm after using Angiopohl?

Flushed skin, particularly affecting the face and neck, is a commonly reported symptom. This effect is directly related to the drug's powerful vasodilating action, which causes blood vessels to widen, increasing blood flow near the skin's surface.

How should Angiopohl be stored and disposed of?

How to Store and Dispose of Angiopohl?

Angiopohl (Nitroglycerin) must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68 F to 77 F). Storage areas must protect the product from light and moisture. It is strictly required to not refrigerate or freeze the medicine. The product must remain in its original, tightly closed container and be kept away from fire or flame due to the presence of volatile solvents. Angiopohl must always be stored securely, out of the sight and reach of children.

Do not flush unused or expired Angiopohl down the toilet. Dispose of the product through an authorized medicine take-back program or by following local guidelines for the disposal of potent prescription medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angiopohl found in:

A-Z Index: